Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 34.75
Bid: 34.50
Ask: 35.00
Change: 0.00 (0.00%)
Spread: 0.50 (1.449%)
Open: 34.75
High: 34.75
Low: 34.75
Prev. Close: 34.75
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of Acquisitions

8 Aug 2007 07:00

China Real Estate Opportunities Ltd08 August 2007 CHINA REAL ESTATE OPPORTUNITIES LIMITED Completion of Acquisitions, Publication of Circular, Notice of EGM and appointments at Treasury Holdings China Completion of Acquisitions In its admission document published on 10 July 2007, China Real EstateOpportunities Limited ("CREO" or "the Company") referred to agreements it hadentered into to acquire the City Centre and Central Plaza properties in Shanghaias key components of its initial portfolio. The Company is pleased to announcethat the acquisition of these properties has now been completed. City Centre has been acquired for £274,799,860, with financing provided byCredit Suisse, and Central Plaza has been acquired for £72,838,517, withfinancing provided by AAReal Bank. City Centre consists of a retail and officecomplex in the Hongqiao district of Shanghai, with an existing gross floor areaof some 187,650 square metres, and a site on which the company plans toconstruct a mixed-use development of some 77,500 square metres. Central Plaza isa 19-storey office building overlooking People's Square in Shanghai having agross floor area of 47,247 square metres. Circular The Company will today distribute a circular to shareholders together with anotice of Extraordinary General Meeting to be held on 3 September 2007. Thepurpose of this circular is to seek shareholders' authority to enable theCompany to make market purchases of its own shares and, in order to facilitatethis, to approve the requisite waiver by the Panel on Takeovers and Mergersunder Rule 9 of the City of Code on Takeovers and Mergers (the "Rule 9 Waiver"). In the period since the Company's shares were admitted to AIM, market conditionsfor equities providing exposure to property markets both in the UK and elsewherehave deteriorated markedly. In the circumstances, the Board believes that itwould be in the interests of shareholders as a whole for the Company to have theflexibility to stand in the market place as a potential purchaser of its ownshares. The Directors, advised by Teather & Greenwood, are recommending shareholders tovote in favour of the resolution to purchase its own shares and the IndependentDirectors, advised by Teather & Greenwood, are recommending shareholders to votein favour of the resolution to approve the Rule 9 Waiver. Appointments CREO also announces the appointments of Richard David and Richard Ding to thepositions of Managing Director and General Counsel of Treasury Holdings China("THC") respectively. THC is CREO's investment manager with responsibility formanaging its existing property portfolio, sourcing additional real estateinvestments and making investment decisions, subject to overall supervision bythe Board of Directors of CREO. Richard David has joined THC from Macquarie Bank Limited, where he was managingdirector of Macquarie Real Estate Capital China. Richard has since 1999 overseenthe operations of Macquarie China, including several business units operatingwithin the real estate sector across China. Richard has extensive experience inall facets of transactional activity and in real estate development, assetacquisitions, finance, tax, corporate structures and investor relations. InMacquarie he had ultimate responsibility for staff and financial management. Richard Ding has been appointed General Counsel of THC. In this position,Richard has responsibility for all legal matters for THC. Prior to joining THC,Richard was General Counsel, and Director, Strategy & Corporate Transactions forglobal automotive supplier Visteon Corporation's Asia Pacific operations.Previously Richard was Managing Director of Concord Venture Capital Group, aleading Asia Pacific venture capital firm, gaining extensive experience withincorporate finance, mergers and acquisitions, and venture investment with a focuson cross-border transactions in or involving Asia Pacific and China. Rob Tincknell, who became Managing Director of THC in 2006, has been appointedDeputy Chairman of THC. He is also a Director of CREO. Rob Tincknell commented: "We are delighted to have made appointments of this calibre to support CREO'soperations in China. Both have experience and expertise in China and will provevaluable additions to the substantial resources that Treasury Holdings havealready committed here. Both Richard Barrett and myself will remain in Shanghaifull time, underlining the significance and focus we are bringing to ouroperations here." CREORay Horney Tel: + 44 (0) 1273 775 225Richard Barrett Tel: + 862 1 5385 8369Robert Tincknell Tel: + 862 1 5385 8369 Teather & Greenwood Tel: + 44 (0) 20 7426 7736Paul FinchamJonathan BecherRobert Naylor Bankside Consultants Ltd Tel: + 44 (0) 20 7367 8888Simon RothschildOliver Winters Murray ConsultantsElizabeth Headon Tel: + 353 1 498 0300 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th May 20247:00 amRNSCreo Medical receives King’s Award for Enterprise
25th Apr 20247:00 amRNSNotice of Results
24th Apr 20247:00 amRNSNHS Speedboat data demonstrates savings
20th Mar 20244:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSWelsh Labour Leader visits Creo’s facilities
13th Mar 20243:05 pmRNSHolding(s) in Company
11th Mar 20242:00 pmRNSLTIP Awards
6th Mar 20244:35 pmRNSHolding(s) in Company
1st Mar 20247:00 amRNSMicrowave Lung Ablation Update
7th Feb 20249:12 amRNSTrading Update - Replacement
7th Feb 20247:00 amRNSTrading Update
5th Feb 20247:00 amRNSStrategic Collaboration with Khalifa University
31st Jan 20247:00 amRNSSpeedboat® UltraSlim roll-out reaches Asia Pacific
22nd Jan 20247:00 amRNSAward of Shares under Share Incentive Plan
10th Jan 20247:00 amRNSFirst use of Speedboat® UltraSlim in Latin America
15th Dec 20237:00 amRNSFirst use of Speedboat® UltraSlim in the USA
13th Dec 20237:00 amRNSFirst European Speedboat® UltraSlim procedure
7th Nov 20237:00 amRNSCapital Markets Day
1st Nov 20237:00 amRNSSpeedboat® UltraSlim: US FDA Clearance
25th Oct 20237:00 amRNSSB UltraSlim: EU launch accelerated by 18 months
16th Oct 202310:16 amRNSChange of Nominated Adviser and Joint Broker
12th Oct 20237:00 amRNSInvestor Presentation
12th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSNotice of Results
16th Aug 20237:00 amRNSRoyal Oldham SSD service update
3rd Aug 20237:00 amRNSHalf Year Trading Update
28th Jul 20237:00 amRNSTotal Voting Rights
24th Jul 202310:40 amRNSAward of Shares under Share Incentive Plan
6th Jul 202311:33 amRNSIssue of Equity and TVR
27th Jun 20231:15 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement & Directorate Succession Planning
26th Jun 20237:00 amRNSFirst upper GI Speedboat procedure in Europe
22nd Jun 20237:00 amRNSAppointment of Marco Scarci
19th Jun 20237:00 amRNSSpeedboat Inject upper GI clearance in Europe
1st Jun 20237:00 amRNSSpeedboat™ Inject selected by NICE for assessment
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20237:00 amRNSFirst in-human milestone for MicroBlate™ Flex
17th May 20237:00 amRNSRoyal Oldham Hospital Agreement
15th May 20237:00 amRNSAttendance at Digestive Disease Week
26th Apr 20237:00 amRNSFinal Results
14th Apr 20237:00 amRNSAlbyn Medical earn out update
31st Mar 202310:45 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSMicroBlate™ Flex clinical study
13th Mar 20236:13 pmRNSDirector/PDMR and PCA Share Dealings
13th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 202310:25 amRNSResult of GM
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.